| Name | Title | Contact Details |
|---|
We protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. Our products reach millions of people every day, as we fight to improve global access to the highest quality hygiene, wellness and nourishment. We`re a growing community of 40,000+ diverse, talented entrepreneurs, and the driving force behind some of the world`s most loved and trusted brands. Our portfolio includes household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Lysol, Dettol, Harpic, Cillit Bang, Finish and Vanish. Hygiene, Health and Nutrition are the focus areas of our business, and the categories under which our brands are organised. Each area is dedicated to building sustainable solutions that will help us address the challenges presented by global mega-trends like urbanisation, climate change and digital transformation. These global pressures are challenging public health systems and increasing the need for improved hygiene products, services and education. We continuously innovate in areas like personalised nutrition, wellness, and digital health and hygiene so that individuals, families and communities can live cleaner, healthier lives.
Ramp Health is a company that provides comprehensive healthcare and safety services to employer, health plan, and government clients.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Hoosier Oncology Group is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Simulation Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Denver, CO. To find more information about Medical Simulation Corporation, please visit www.medsimulation.com.